Eyevance Pharmaceuticals Holdings Inc

Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M

by | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE